Anti-DcR1 抗体 (ab2087)
Key features and details
- Rabbit polyclonal to DcR1
- Suitable for: ICC/IF, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-DcR1 antibody
DcR1 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to DcR1 -
由来種
Rabbit -
アプリケーション
適用あり: ICC/IF, WBmore details -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Synthetic peptide corresponding to Human DcR1 aa 100-200 (extracellular).
Database link: O14798 -
ポジティブ･コントロール
- HeLa whole cell lysate.
-
特記事項
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumour cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy-receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.2
Preservative: 0.02% Sodium azide -
Concentration information loading... -
精製度
Affinity purified -
一次抗体 備考
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumour cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy-receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab2087の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| ICC/IF |
Use a concentration of 10 µg/ml.
|
|
| WB |
Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 65 kDa. Can be blocked with DcR1 peptide (human).
|
| 特記事項 |
|---|
|
ICC/IF
Use a concentration of 10 µg/ml. |
|
WB
Use a concentration of 0.5 - 1 µg/ml. Predicted molecular weight: 65 kDa. Can be blocked with DcR1 peptide (human). |
ターゲット情報
-
機能
Receptor for the cytotoxic ligand TRAIL. Lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand. -
組織特異性
Higher expression in normal tissues than in tumor cell lines. Highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart. -
配列類似性
Contains 3 TNFR-Cys repeats. -
翻訳後修飾
N-glycosylated and O-glycosylated. -
細胞内局在
Cell membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 8794 Human
- Omim: 603613 Human
- SwissProt: O14798 Human
- Unigene: 655801 Human
-
別名
- Antagonist decoy receptor for TRAIL/Apo 2L antibody
- Antagonist decoy receptor for TRAIL/Apo-2L antibody
- CD263 antibody
see all
画像
-
Western blot - Anti-DcR1 antibody (ab2087)All lanes : Anti-DcR1 antibody (ab2087) at 1 µg/ml
Lane 1 : Hela cell lysate
Lane 2 : Mouse liver tissue lysate
Lane 3 : Rat liver tissue lysate
Predicted band size: 65 kDaWestern blot analysis of DcR1 in HeLa cell (A), mouse (B) and rat (C) liver tissue lysates with anti-DcR1 (ED2) at 1
µ g/ml. -
Immunocytochemistry/ Immunofluorescence - Anti-DcR1 antibody (ab2087)ab2087 at 10µg/ml staining DcR1 in rat liver tissue by ICC/IF
-
Immunocytochemistry/ Immunofluorescence - Anti-DcR1 antibody (ab2087)Immunofluorescence of DcR1 in Rat Liver cells using ab2087 at 20 ug/ml.
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (6)
ab2087 は 6 報の論文で使用されています。
- Wang Z et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther 5:40 (2020). PubMed: 32327638
- Jin W et al. Ischemic Preconditioning Upregulates Decoy Receptors to Protect SH-SY5Y Cells from OGD Induced Cellular Damage by Inhibiting TRAIL Pathway and Agitating PI3K/Akt Pathway. Mol Neurobiol 57:3658-3670 (2020). PubMed: 32564286
- Rath C et al. Comparison of different label-free imaging high-throughput biosensing systems for aptamer binding measurements using thrombin aptamers. Anal Biochem 583:113323 (2019). PubMed: 31129134
- Li N et al. The role of Zeb1 in the pathogenesis of morbidly adherent placenta. Mol Med Rep 20:2812-2822 (2019). PubMed: 31322233
- You C et al. ß-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors. Int J Oncol 53:2258-2268 (2018). PubMed: 30132512
- Ziauddin MF et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther 17:550-9 (2010). PubMed: 20182517
